Kestra Medical (KMTS) Q2 2026 earnings review
Scaling Fast, spending Faster: Margins Break 50%
Kestra delivered a textbook 'beat and raise' for a growth-stage medtech. Revenue surged 53% YoY to $22.6M, driven by a 54% jump in prescriptions. The standout metric was Gross Margin breaking the psychological 50% barrier (50.6% vs 39.6% last year), validating the unit economics of their rental model. However, growth is expensive: SG&A expenses nearly doubled YoY, widening the Net Loss to $32.8M. With a fresh $148M equity raise post-quarter, the balance sheet is fortress-strong, but cash burn remains the primary friction point.
🐂 Bull Case
Gross margin expanded 1,100 basis points YoY to 50.6%. As volume scales and the mix of 'in-network' patients rises, the high-margin nature of the device rental model is finally showing up in the numbers.
Kestra ended Q2 with $175M cash, then raised another $148M net in December. With ~$323M in pro-forma liquidity, financing risk is effectively zero for the foreseeable future, allowing aggressive sales investment.
🐻 Bear Case
SG&A expenses ballooned 78% YoY to $38.3M—significantly higher than the 53% revenue growth. The company is spending $1.70 in SG&A for every $1.00 of revenue generated, indicating a very expensive customer acquisition phase.
Despite margin expansion, the Net Loss deepened to $32.8M (from $20.6M a year ago). While Adjusted EBITDA margin is improving effectively, the absolute cash burn is increasing as the company chases market share.
⚖️ Verdict: 🟢
Bullish. The 50% gross margin crossover is a pivotal moment that proves the business model works at scale. While the burn rate is high, the massive cash pile ($300M+) buys them years of runway to execute. The revenue acceleration validates the demand.
Key Themes
Gross Margin Breakout
Accelerating. Gross margin jumped from 45.7% in Q1 to 50.6% in Q2. Management attributes this to volume leverage (spreading fixed costs over more device rentals) and a higher mix of 'in-network' patients, which typically carry better reimbursement rates. This trend validates the long-term profitability potential.
Prescription Volume Velocity
Accelerating. ASSURE system prescriptions grew 54% YoY to 4,696. This matches the revenue growth rate, indicating that pricing/mix remained stable while volume surged. This volume growth is the primary engine for the margin expansion mentioned above.
SG&A Efficiency Lag
Deteriorating. While revenue grew 53%, SG&A expenses grew 78% YoY. The company is aggressively hiring sales staff and building public company infrastructure. The gap between revenue growth and expense growth needs to close for the company to chart a path to breakeven.
In-Network Strategy Paying Off
Management noted in the Q1 call (prior quarter) that in-network mix was approaching 80%. The Q2 results confirm the financial impact of this shift: higher reimbursement certainty and improved revenue cycle management directly fed the gross margin beat.
Other KPIs
Stable/Fortress. Reported $175M at quarter end, plus ~$148M net proceeds from the December offering. This massive liquidity position removes any near-term financing overhang and allows the company to absorb current operating losses comfortably.
Stable (Percentage basis). While the absolute loss grew from $(16.1)M last year, as a percentage of revenue, the margin improved from -109% to -87%. The company is losing less money per dollar of revenue, but losing more total dollars due to scale.
Guidance
Accelerating. Raised from prior $88M. Implies ~$49M in H2 (avg $24.5M/quarter) vs $42M in H1. This suggests sequential growth will continue, with implied YoY growth remaining above 50%.
Key Questions
SG&A Leverage Timeline
SG&A grew significantly faster than revenue this quarter (78% vs 53%). At what revenue run-rate do you expect to see operating leverage where expense growth falls below revenue growth?
Gross Margin Ceiling
You broke 50% GM earlier than many expected. With the current in-network mix and volume, is the long-term target of 70%+ accelerated, or do we face structural headwinds in the near term?
Non-Recurring Costs
Q2 included $1.0M in non-recurring costs. Can you specify what these related to and if we should model a clean OpEx run-rate for Q3?
Cash Deployment
With ~$323M in pro-forma cash, does the capital allocation strategy change? Will you accelerate territory expansion faster than the current plan, or is this purely a defensive buffer?